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Abstract
Background: Epigenetics is defined as heritable changes in gene expression that are not based on changes in the DNA
sequence. Posttranslational modification of histone proteins is a major mechanism of epigenetic regulation. The kinase
PRK1 (protein kinase C related kinase 1, also known as PKN1) phosphorylates histone H3 at threonine 11 and is involved in
the regulation of androgen receptor signalling. Thus, it has been identified as a novel drug target but little is known about
PRK1 inhibitors and consequences of its inhibition.
Methodology/Principal Finding: Using a focused library screening approach, we identified the clinical candidate
lestaurtinib (also known as CEP-701) as a new inhibitor of PRK1. Based on a generated 3D model of the PRK1 kinase using
the homolog PKC-theta (protein kinase c theta) protein as a template, the key interaction of lestaurtinib with PRK1 was
analyzed by means of molecular docking studies. Furthermore, the effects on histone H3 threonine phosphorylation and
androgen-dependent gene expression was evaluated in prostate cancer cells.
Conclusions/Significance: Lestaurtinib inhibits PRK1 very potently in vitro and in vivo. Applied to cell culture it inhibits
histone H3 threonine phosphorylation and androgen-dependent gene expression, a feature that has not been known yet.
Thus our findings have implication both for understanding of the clinical activity of lestaurtinib as well as for future PRK1
inhibitors.
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Introduction
Epigenetics is defined as inheritable changes in gene
regulation that are not determined by alterations in the genome
[1]. Epigenetic processes have clear implications for the
pathology of human disease [2], and hence new inhibitors of
these are highly interesting for drug discovery [3]. Among
diverse histone modifications [4], phosphorylation of histones is
not so well studied, especially with regard to drug discovery.
Most reports are on Aurora kinases which are rather involved
in the control of mitosis [5]. Another kinase involved in mitosis
that is acting on histones is haspin [6,7]. The kinases PKC-
betaI [8] and PRK1
a (also termed PKN1) [9] play important
roles in activating gene transcription [10] in the course of
androgen receptor signalling and PRK1 is considered to be a
promising target for the treatment of prostate cancer. In the
search for new PRK1 inhibitors we performed a focussed
library screening to identify new hits and evaluate reference
kinase inhibitors in comparison. We identified the clinical
candidate lestaurtinib (also known as CEP-701) as a new potent
inhibitor of the epigenetic kinase PRK1.
Results
Focused Library Screening
As a starting point for the search of new PRK1 inhibitors, we
used the Biomol Kinase and Phosphatase inhibitor library (n=84,
see Figure S4, S5 and S6) for an initial screening at 100 nM
threshold concentration. This screening identified only the
bisindolyl-maleimide (BIM) Ro318220 and the structurally related
staurosporine as hits (more than 40% binding relative to
staurosporine at 100 nM) (see Figure 1 and Table 1). Ro318220
was already known to inhibit PRK1 [9]. We further screened a
200 compound in-house library of commercially available and
generic kinase inhibitors, resp. inhibitor candidates. Those
included standard kinase inhibitors like erlotinib, lapatinib,
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been used to profile different kinases before. The inhibitors K252a
and lestaurtinib and additionally SB216763 (interaction data not
shown) were selected for the docking study based on their
structural similarity to staurosporine and Ro318220. The
staurosporine analogs all show a similar binding model. K252a
inhibits trkA, VEGFR2 and MLK1 in the two-digit nM region
and is known to have a selectivity over PKC about 10-20fold [11].
Lestaurtinib was reported to inhibit trkA, B and C [12], JAK [13]
and FLT3. Because of the inhibition of FLT3, it is studied
clinically in myelofibrosis and AML [14,15]. Lestaurtinib and
K252a were both bound by PRK1 with high affinity (see Table 1).
Lestaurtinib was chosen for further biological evaluation in our
study due to its advanced development status and showed
inhibition of androgen gene responsive gene transcription.
Molecular Modelling
A model of human protein C related kinase 1 (PRK1) was
generated by homology modeling to rationalize our findings for
further optimization studies. The model was based on similarity of
PRK1 to protein kinase C theta (PKC-theta) and was used for
docking studies. Since the available crystal structures of PKC
subtypes in complex with inhibitors show all the active kinase
conformation, the PRK1 model represents also the active
conformation with the classical DFG-in motif (Figure 2) [16].
The 84 compounds of the Biomol kinase inhibitor library, which
were tested in the in-vitro assay, were docked into the ATP
binding pocket of PRK1. We used three different docking methods
(GOLD [17], GLIDE [18] and ParaDockS [19]) and five different
scoring functions (ChemScore, GoldScore, GlideScore, Para-
DockS p-Score and AMBER GBSA score [20,21]). In total, 63
compounds could be successfully docked into the ATP binding
pocket. In general, the different docking methods yielded similar
results even if the ranking of the compounds was found to be
different (Table S1). The two active inhibitors from the Biomol
compound collection, staurosporine and Ro318220, were top-
ranked by some of the scoring functions. Generally, in docking and
virtual screening studies a better discrimination between actives
and decoys is observed by using a consensus score based on a
variety of different scoring methods [22,23]. In the present study,
we also calculated a consensus score using the five normalized
scoring functions Chemscore, Goldscore, Glidescore, ParaDockS
p-score and GBSA score. Using the consensus scoring, a clear
discrimination between the highly active inhibitors staurosporine
(Score 9.23) and Ro318220 (Score 9.51) and the inactive
compounds (including the inactive kinase inhibitors shown in
Figure 1) could be obtained. The only molecule which gave a
similar high score was the related bisindolylmaleimide derivative
31 (Score of 8.84, Table S1, Figure S5) which did not show any in-
vitro activity below 100 nM (data not shown).
The docking arrangement of staurosporine in the active site of
PRK1 shows that the ligand is completely buried in the ATP
binding pocket (Figure 2). Most important, the lactame and
maleimide groups of staurosporine and Ro318220, respectively,
form two hydrogen bonds to Glu696 and Ser698, which are part
of the hinge region of PRK1 (Figure 3A and 3D). Van-der-Waals
interactions are observed with the gatekeeper residue Met695, as
well as with Val629, Phe626, Leu747, and Phe904, respectively.
Furthermore, hydrogen bonds between the protonated amino
group of staurosporine as well as the thiourea group of Ro318220
and Asp744 can be observed. The amino group of staurosporine is
also involved in a hydrogen bond with a conserved water molecule
and the backbone CO of Asp744.
The analysis of the docking poses of K252a and lestaurtinib
showed that both compounds interact in the same way with the
ATP binding pockets as staurosporine (Figure 3B and 3C). Besides
the interaction with the hinge region, the polar substituents at the
tetrahydrofuran ring system interact with a conserved water
molecule bound at Asp744 and Asn745.
Cellular Testing
We then analyzed the effect of lestaurtinib on androgen
responsive LNCaP prostate cancer cells (see Figure 4) [24]. An
effect on androgen receptor mediated signalling was measured
using the quantitation of mRNA expression of several known
androgen receptor target genes. Lestaurtinib blocks the expression
of Transmembrane protease, serine 2 (TMPRSS2) [25], Insulin-
like growth factor-1 (IGF1-R27) [25], CXC chemokine receptor 4
(CXCR429) [26], Homeobox protein Nkx-3.1 (NKX3.1) [27], male
germ cell-associated kinase (MAK30) [28], musculoaponeurotic
fibrosarcoma oncogene homolog (MAF) [29], nuclear receptor
subfamily 4, group A, member 1 (N4A1) [29], Gene regulated in
breast cancer I (GREB1) [30] and FK506 binding protein 5
(FKBP5) [31] at 5 mM but does not reduce expression of the
androgen-independent glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) gene [31]. In the same range of concentration,
lestaurtinib caused a hypophosphorylation at histone H3 threo-
nine 11 (Figure S7).
Discussion
Histone modifications have become a focus of drug discovery
efforts. Inhibitors of the enzymes that establish these modifica-
tions are also valuable tools to probe signalling pathways. We
identified the clinical candidate lestaurtinib as an inhibitor of
the kinase PRK1 which affects epigenetic regulation and
androgen receptor signalling. This new mode of action of
lestaurtinib has not been known so far and could be important
to understand its activity in clinical settings. The structural
similarities of lestaurtinib in comparison to staurosporine make
it possible that other kinases than PRK1 may contribute to the
observed gene regulatory effects in LNCaP cells. Nevertheless, it
is of great importance that lestaurtinib has an effect on
epigenetic histone modifications and reduces androgen depen-
dent gene expression significantly in prostate cancer cells. This
fact should be taken into consideration for future assessments in
clinical settings.
In addition to the in vivo effects of lestaurtinib, the identification
of lestaurtinib and K252a as novel PRK1 inhibitors and the lack of
inhibition of established kinase inhibitors with scaffolds such as
anilinoquinazolines, anilinophthalazines or diarylimidazoles pro-
vides valuable information for the design of further and more
selective PRK1 inhibitors as potential therapeutics for androgen-
dependent cancers.
Materials and Methods
Kinase Assay
Kinase inhibitors were purchased from Sigma-Aldrich (Les-
taurtinib) and Biomol (Ro318220) and used as obtained. Purity
was .93% (w/w) in all cases as indicated by the supplier.
Inhibitor screening was carried out with the LanthaScreen
TM
Eu Kinase Binding Assay Kit (Invitrogen) with final assay
concentrations of 5 nM for PRK1 (Proqinase, Freiburg), 2 nM
LanthaScreen Eu-anti-GST Antibody (Invitrogen) and 10 nM
Kinase Tracer 236 (Invitrogen). The assay was performed in
384-well microtiter plates (Perkin Elmer, Rodgau). The final
Lestaurtinib Inhibits Histone Phosphorylation
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EnVision 2102 Multilabel Reader (PerkinElmer, Rodgau,
Excitation: 340 nm, 1
st Emission: 665 nm, 2
nd Emission:
615 nm, Delay Time 100 ms, Integration Time 200 ms). The
kinase inhibitor library was purchased from Biomol (academic
size, n=84 - former CAT#2831A, Figure S4, S5, S6). IC50
determinations were performed three independent times, each
in triplicates.
Figure 1. Known and newly identified PRK1 inhibitors.
doi:10.1371/journal.pone.0034973.g001
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Al0l calculations were performed on a Pentium IV 2.2 GHz
based Linux cluster. Since the crystal structure of the human
PRK1 kinase (Uniprot entry Q16512) is not known, a homology
model was generated. A BLASTP search [32] was performed for
the human PRK1 amino acid sequence. The highest similarity was
found for the related kinase PKCtheta. The overall sequence
identity between the human PRK1 sequence and the sequence
derived from PKC-theta is 49% with only small gaps or insertions
in the aligned region. The sequence alignment was done with
ClustalW [33] (Figure S1). The model was generated with the
program Modeller using the coordinates of the PKC-theta X-ray
structure 2jed (Resolution 2.32 A ˚) in the active conformation. The
superimposition of the PRK1 model and the PKC-theta X-ray
structure yielded an RMSD value of 0.73 A ˚ for the backbone
atoms illustrating the high structural similarity of both kinases. The
stereochemical quality of the resulting PRK1 model was analyzed
using the program PROCHECK [34]. Hydrogen atoms and
AMBER partial charges were assigned. The model was energy-
minimized using the AMBER force field [35]. The refinement led
to a model with excellent stereochemical quality with 90.1% of the
phi and psi angle values in the most favored regions, and 8.5% in
additionally allowed regions (Figure S2). No residue in the model is
located in the disallowed region.
Ligand Docking
We used three different docking programs (GOLD 4.1 [17],
GLIDE [18] and ParaDockS [19]) to dock all molecules into the
PRK1 ATP binding site. For all docking runs the default settings
of the program were used. The binding site for PRK1 was defined
on Glu696 with a radius of 15 A ˚ covering the ATP binding
pocket. A conserved water molecule observed in the X-ray
structures of PKCbeta and PKCtheta was considered to be part of
the protein. Goldscore, Chemscore, Glidescore, ParaDockS p-
Score and AMBER GBSA [20,35] score were chosen as fitness
functions. For each molecule, 30 docking runs were performed.
The resulting solutions were clustered on the basis of the heavy
atom RMSD values (1 A ˚). First, we tested whether the docking
programs are able to reproduce the binding mode of the bound
ligands NVP-XAA228, Biomol 33 (Ro318220), and staurosporine
as observed in the X-ray structures of PKC-theta and PKC-beta,
respectively (pdb codes 2jed.pdb, 1xjd.pdb [36] and 1i0e.pdb
[37]). Highest accuracy was obtained using the GOLD program
and Goldscore as fitness function. The RMSD values between the
top-ranked Goldscore docking solution and the crystal structure of
the inhibitors are 0.78 A ˚, 0.71 A ˚ and 0.49 A ˚ (heavy atoms)
respectively, demonstrating the usability of the applied docking
programs for reproducing the experimentally determined struc-
tures of the kinase inhibitor complexes.
Molecular Dynamics Simulations
The stability of the derived PRK1-inhibitor complexes was
examined by means of molecular dynamics (MD) simulations. The
most active inhibitor staurosporine was used for this simulation.
Table 1. PRK1 in vitro binding.
Inhibitor IC50 ± SEM [nM]
Staurosporine 0.8 6 0.2
Ro318220 28.6 6 6.5
K252a 3.2 6 0.6
Lestaurtinib 8.6 6 0.9
doi:10.1371/journal.pone.0034973.t001
Figure 2. Interaction of staurosporine (carbon atoms in green) at the ATP binding pocket of PRK1. The molecular surface of the binding
pocket is shown. Besides the hydrogen bonds with the hinge region, the protonated amino group of staurosporine donates hydrogen bonds (shown
as orange dashed lines) to Asp744 and a conserved water molecule (shown in red).
doi:10.1371/journal.pone.0034973.g002
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AMBER 1999 force field [38,39]. The ligand force fields
parameters were taken from the general Amber force field
(GAFF), whereas AM1 ESP atomic partial charges were assigned
to the inhibitor. The complexes were soaked in a box of TIP3P
water molecules with a margin of 10 A ˚. Prior to the free MD
simulations, two steps of relaxation were carried out; in the first
step, we kept the protein fixed with a constraint of 500 kcal
mol
21A ˚ 21. In the second step, the inhibitor structures were
relaxed for 0.5 ps, during which the protein atoms were restrained
to the X-ray coordinates with a force constant of 500 kcal
mol
21A ˚ 21. In the final step, all restraints were removed and the
complexes were relaxed for 1 ps. The temperature of the relaxed
system was then equilibrated at 300 K through 20 ps of MD using
2 fs time steps. A constant volume periodic boundary was set to
equilibrate the temperature of the system by the Langevin
dynamics [40] using a collision frequency of 10 ps
21 and a
velocity limit of 5 temperature units. During the temperature
equilibration routine, the complex in the solvent box was
restrained to the initial coordinates with a weak force constant
of 10 kcal mol
21A ˚ 21. The final coordinates of the temperature
equilibration routine (after 20 ps) were then used to complete a
1 ns molecular dynamics routine using 2 fs time steps, during
which the temperature was kept at 300 K by the Langevin
dynamics using a collision frequency of 1 ps
21 and a velocity limit
of 20 temperature units. The pressure of the solvated system was
equilibrated at 1 bar at a certain density in a constant pressure
periodic boundary by an isotropic pressure scaling method
employing a pressure relaxation time of 2 ps. The time step of
the free MD simulations was 2 fs with a cutoff of 9 A ˚ for the non-
bonded interaction, and SHAKE [41] was employed to keep all
bonds involving hydrogen atoms rigid. Electrostatic interactions
were computed using the Particle Mesh Ewald method [42]. The
MD simulation of the PRK1-staurosporine complex was per-
formed in total for 10 ns. The RMSD plot is shown in Figure S3.
Database
The 3D structures of the Biomol compounds (Figure S4, S5, S6)
were generated using the Omega program (OpenEye Software).
Figure 3. Details of the binding of (A) staurosporine (green), (B) K252a (orange), (C) lestaurtinib (cyan), and (D) Ro318220 (dark-
yellow) to the PRK1 kinase domain. Common interactions of the inhibitors are hydrogen bonds involving Glu696 and Ser698 of the hinge region,
and van-der-Waals interactions with the gatekeeper residue Met695, as well as with Val629, Phe626, Leu747, and Phe904. In addition, some of the
inhibitors interact with Asp744, Asn745 and a conserved water molecule (red sphere) nearby the Mg
2+ binding site of the kinase. The backbone is
shown as a purple ribbon. Only relevant amino acids are displayed. Hydrogen bonds are shown as dashed orange colored lines.
doi:10.1371/journal.pone.0034973.g003
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34973All possible isomers and tautomers were generated, which resulted
in 265 3D structures. All generated isomers were used for the
docking study.
AMBER GBSA Scoring
The docked poses were energy-minimized using the AMBER
force field and the GBSA continuum model [21]. For each
molecule the best scoring pose was selected for comparison with
the biological data. The minimization was carried out using a
combination of steepest descent and conjugate gradient algorithm
with a root mean square of gradient at 0.001 kcal/mol. AM1-
BCC charges were assigned for the inhibitors, and the Amber99
force field was applied for the protein. The non-bonded cutoff was
set at 16 A ˚. All heavy atoms of the protein were tethered with a
force constant of 100 kcal/mol, whereas the inhibitor atoms were
relaxed during the energy minimization process. The binding free
energy DG is calculated as:
DGbind~DEMMzDGsolvzDGSA
where DEMM is the difference in energy between the complex and
the sum of the energies for the free ligand and free protein, DGsolv
is the difference in the GBSA solvation energy of the complex and
the sum of the solvation energies for free ligand and free protein,
and DGSA is the difference in the surface area energy of the
complex and the sum of the surface area energies for free ligand
and free protein.
RT-qPCR Analysis
Effects on androgen receptor target genes were determined using
real-time quantitative PCR. LNCaP cells were washed once with
PBS and then starved for 24 hours in phenol-red-free RPMI1640
supplemented with 0.5% double-stripped fetal calf serum (dsFCS).
Cells were then treated or not with lestaurtinib (final concentration
5 mM) as indicated. If cells were not treated with lestaurtinib,
DMSO was added as a vehicle. 10 minutes after adding lestaurtinib
or the vehicle, cells were treated overnight with or without R1881
(10
29 M) as indicated. DNaseI-treated RNA, isolated using Trizol
(Invitrogen), was used for reverse transcription. Quantitative PCR
was performed in a LightCycler 480 (Roche). Product formation
was detected by incorporation of SYBR green I using ROX as a
passive reference (ABgene). For qRT-PCR, the following primers
were used: TMPRSS2 [25] 59-TCACACCAGCCATGATCTGT-
39 and 59-CTGTCACCCTGGCAAGAATC-39; IGF1-R [25] 59-
CTGTATGCCTCTGTGAACC-39 and 59-TAGACCATCCCA-
AACGAC-39; NKX3.1 [27] 59-AGAACGACCAGCTGAGCAC-
39 and 59-AAGACCCCAAGTGCCTTTCT-39; CXCR4 [26] 59-
CTGTGAGCAGAGGGTCCAG-39 and 59-ATGAATGTCCA-
CCTCGCTTT-39; MAK [28] 59-TGGACTTGCAAGAGAAT-
TAAGGT-39 and 59-CTTCAGGGGCACGATACC-39; MAF
[29] 59-AGCGGCTTCCGAGAAAAC-39 and 59-GCGAGTGG-
GCTCAGTTATG-39; N4A1 [29] 59-ACAGCTTGCTTGTC-
GATGTC-39 and 59-GGTTCTGCAGCTCCTCCAC-39; GREB1
[30] 59-AAGCTGAGCAGCACAGACAA-39 and 59-GGCT-
TCTCTTCTCCGAGGTAG-39; FKBP5 [31] 59-TTTTTGAG-
ATTGAGCTCCTTGA-39 and 59- TTGTGTTCACCTTTGC-
CAAC-39; GAPDH [31] 59-GAGTCCACTGGCGTCTTCAC-39
and 59-GTTCACACCCATGACGAACA-39. Bars represent mean
+ SD (n=5). P-value: ns = non significant; * = ,0.05; **,0.01;
***,0.001.
Western Blot Analysis
LNCaP human prostate adenocarcinoma cells were grown in
RPMI1640 medium (PAA) containing fetal bovine serum (PAA)
10% (v/v), penicillin (PAA) 1% (v/v), streptomycin (PAA) 1% (v/
v), L-glutamine (PAA) 1% (v/v) at 37uC and 5% CO2. 2.5 * 10
6
cells were seeded in tissue culture dishes (10 cm) and incubated in
RPMI1640 medium (PAA) containing charcoal stripped fetal calf
serum (PAA) 10% (v/v), penicillin (PAA) 1% (v/v), streptomycin
(PAA) 1% (v/v), L-glutamine (PAA) 1% (v/v). 24 h after seeding
lestaurtinib or Ro318220 (final concentration in each case 4.5 mM)
dissolved in growth medium (charcoal stripped bovine serum 10%
(v/v), penicillin 1% (v/v), streptomycin 1% (v/v), L-glutamine 1%
(v/v), DMSO 1% (v/v), dihydrotestesterone 0.1 nM) were added
and incubated for 18 h. LNCaP cells incubated with DMSO (1%
(v/v)) were used as a control. Following inhibitor treatment, cells
were washed once with ice cold PBS, lysed with nuclei isolation
buffer (Sucrose 250 mM, Tris-HCl 20 mM, NaCl 150 mM,
IGEPAL-CA 630 0.1% (v/v), CaCl2 0.2 mM, MgCl2 1.5 mM,
DTT 1 mM, Pepstatin 1 mM, Protease Inhibitor Cocktail Mix
(Sigma), PhosStopH (Roche), pH 8.0). Histones were acid
extracted (H2SO4 0.4 N, DTT 1 mM, Pepstatin 1 mM, Protease
Inhibitor Cocktail Mix (Sigma), PhosStopH (Roche)) overnight.
Protein concentrations of histone extracts were determined
using BCA Protein Assay (Pierce). 5 mg of proteins were separated
by SDS-gel electrophoresis (15% polyacrylamide gel) and
transferred to a RotiH-PVDF membrane (Roth). The membrane
was then blocked with non-fat dry milk (Roth, 5% (w/v), TBS,
Tween 20 0.1% (v/v)) and probed with anti-H3T11ph (Active
Motif) 1:1000 and anti-H3 (Upstate) 1:5000 as a loading control.
Canon CanoScan Lide 50 was used to acquire the image of the
blot and Adobe Photoshop 5.0 was used to process the image.
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